{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:06:39Z","timestamp":1783649199620,"version":"3.55.0"},"reference-count":10,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,12]]},"DOI":"10.1182\/blood.2025031748","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:32:06Z","timestamp":1770913926000},"page":"705-707","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["An old but still good friend: chemoimmunotherapy in HCL"],"prefix":"10.1182","volume":"147","author":[{"given":"Enrico","family":"Tiacci","sequence":"first","affiliation":[{"name":"University and Hospital of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mancini","sequence":"additional","affiliation":[{"name":"University and Hospital of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2026021211320351800_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood.2025031243","article-title":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia","volume":"147","author":"Schroeder","year":"2026","journal-title":"Blood"},{"issue":"14","key":"2026021211320351800_bib2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra2406376","article-title":"Hairy-cell leukemia","volume":"391","author":"Falini","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"2026021211320351800_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMc2500911","article-title":"Targetable mutations in BRAF V600E-negative hairy-cell leukemia","volume":"392","author":"Santi","year":"2025","journal-title":"N Engl J Med"},{"issue":"17","key":"2026021211320351800_bib4","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood.2024026894","article-title":"Non-V600E BRAF mutations and treatment for hairy cell leukemia","volume":"145","author":"Arons","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026021211320351800_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2026021211320351800_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-014-2175-0","article-title":"Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases","volume":"94","author":"Leclerc","year":"2015","journal-title":"Ann Hematol"},{"issue":"9","key":"2026021211320351800_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2024.2349700","article-title":"Long-term results of the sequential combination of cladribine and rituximab in hairy cell leukemia","volume":"65","author":"Marvin-Peek","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2026021211320351800_bib8","doi-asserted-by":"crossref","first-page":"63136321","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026021211320351800_bib9","doi-asserted-by":"crossref","first-page":"100888","DOI":"10.1016\/j.blre.2021.100888","article-title":"Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues","volume":"51","author":"Kreitman","year":"2022","journal-title":"Blood Rev"},{"issue":"15","key":"2026021211320351800_bib10","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood.2021013502","article-title":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors","volume":"139","author":"Falini","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/7\/705\/2502978\/blood_bld-2025-031748-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/7\/705\/2502978\/blood_bld-2025-031748-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:32:07Z","timestamp":1770913927000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/7\/705\/566410\/An-old-but-still-good-friend-chemoimmunotherapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031748","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,12]]},"published":{"date-parts":[[2026,2,12]]}}}